Business Context and Reporting Period
Company: Mustang Bio, Inc. (MBIO)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Mustang Bio is a clinical-stage biopharmaceutical company focused on developing novel therapies for solid tumors, specifically malignant brain tumors. The company operates as a majority-controlled subsidiary of Fortress Biotech, Inc. Its primary pipeline consists of MB-101 (IL13Rα2-targeted CAR T-cell therapy) and MB-108 (HSV-1 oncolytic virus), often developed in combination as MB-109. The company has no approved products and generates no product revenue.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1.9) million | $(15.8) million |
| Operating Expenses | $2.4 million | $16.2 million |
| Cash and Cash Equivalents (Year End) | $17.3 million | $6.8 million |
| Accumulated Deficit | $(398.6) million | $(396.7) million |
| Net Cash Used in Operating Activities | $(5.3) million | $(11.4) million |
| Net Cash Provided by Financing Activities | $14.5 million | $11.3 million |
Note: The filing text does not provide specific gross margin or operating margin data as the company has no revenue.
Material Changes vs. Prior Period
- Significant Reduction in Net Loss: Net loss decreased by approximately 88% from $15.8 million in 2024 to $1.9 million in 2025. This was driven by a substantial decrease in total operating expenses ($13.8 million reduction).
- Research and Development (R&D) Expenses: R&D expenses turned negative (a net credit) of $(1.5) million in 2025 compared to $8.4 million in 2024. This reversal was primarily due to a $2.1 million credit from the settlement of aged payables, a $0.4 million gain on lease termination, and reduced costs for clinical trials and outside services.
- Asset Impairment: The company recorded a $3.7 million asset impairment charge in 2024 related to leasehold improvements and equipment. No impairment was recorded in 2025.
- Liquidity Improvement: Cash balances increased from $6.8 million to $17.3 million, primarily due to net proceeds of approximately $14.5 million from equity offerings and warrant exercises in 2025.
- Going Concern Status: The company previously disclosed substantial doubt about its ability to continue as a going concern. Based on the improved cash position and cost reductions in 2025, management concluded that substantial doubt no longer exists as of the filing date.
Guidance, Outlook, and Risks
- Clinical Pipeline Outlook: The company is exploring the initiation of a Phase 1 investigator-sponsored single-institution trial for the combination therapy MB-109 (MB-101 + MB-108) at City of Hope, potentially in the second quarter of 2026. Both MB-101 and MB-108 have received FDA Orphan Drug Designation.
- Capital Requirements: The company expects to continue incurring significant operating losses and negative cash flows. It anticipates needing to raise substantial additional funding to advance clinical development and commercialization efforts. Future fundraising may result in dilution to existing stockholders.
- Key Risks:
- Financial: Reliance on equity financing; potential inability to raise capital on acceptable terms; continued operating losses.
- Development: High risk of clinical trial failure; regulatory approval uncertainties; reliance on third-party manufacturers and research institutions (City of Hope, Nationwide Children's Hospital).
- Corporate Structure: Fortress Biotech, Inc. controls a voting majority of the company and receives an annual 2.5% stock dividend, causing dilution to other shareholders.
- Listing Status: The company previously failed to meet Nasdaq listing requirements but regained compliance in 2025 via a reverse stock split and equity offering. Continued compliance is not guaranteed.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $17.3 million cash balance to fund operations through the anticipated Q2 2026 trial initiation and beyond, given the history of negative operating cash flows.
- Payable Settlements: Confirm the sustainability of the $2.1 million R&D credit derived from aged payable settlements, as this is not indicative of future operating expenses.
- Fortress Biotech Relationship: Review the terms of the Founders Agreement and Management Services Agreement, specifically the 2.5% annual stock dividend and equity fees, to understand ongoing dilution mechanics.
- Clinical Trial Timeline: Monitor the status of the proposed MB-109 Phase 1 trial initiation in 2026 and any regulatory feedback regarding the lead-in cohort requirements.
- Nasdaq Compliance: Track the company's ability to maintain Nasdaq Capital Market listing standards, particularly regarding stock price and shareholder equity.